127 research outputs found
Magnetic Properties of Variable-sized Fe3O4 Nanoparticles Synthesized from Non-aqueous Homogeneous Solutions of Polyols
The magnetic behaviour of well-dispersed monodisperse Fe3O4 nanoparticles with sizes varying between 6.6 and 17.8 nm prepared in a non-aqueous medium was investigated. The smaller nanocrystals exhibit superparamagnetism with the blocking temperatures increasing with the particle size, whereas the biggest particles are ferromagnetic at room temperature. The saturation magnetization values are slightly smaller than that of the bulk material, suggesting the existence of a disordered spin configuration on their surface. The thickness of the magnetically inert shell was estimated from the size variation of the magnetization at 1.9 Å. The dipole–dipole interactions between the particles were tuned by changing the interparticle distances, e.g. by diluting the nanopowders in a non-magnetic matrix at concentrations ranging from 0.25 to 100 wt%. As the strength of the interactions is decreased with dilution, the energy barrier is substantially lowered; this will induce a drastic decrease of both the blocking temperatures and the coercivity with decreasing concentration of the nanoparticles
Magnetic Properties of Variable-sized Fe3O4 Nanoparticles Synthesized from Non-aqueous Homogeneous Solutions of Polyols
The magnetic behaviour of well-dispersed monodisperse Fe3O4 nanoparticles with sizes varying between 6.6 and 17.8 nm prepared in a non-aqueous medium was investigated. The smaller nanocrystals exhibit superparamagnetism with the blocking temperatures increasing with the particle size, whereas the biggest particles are ferromagnetic at room temperature. The saturation magnetization values are slightly smaller than that of the bulk material, suggesting the existence of a disordered spin configuration on their surface. The thickness of the magnetically inert shell was estimated from the size variation of the magnetization at 1.9 Å. The dipole–dipole interactions between the particles were tuned by changing the interparticle distances, e.g. by diluting the nanopowders in a non-magnetic matrix at concentrations ranging from 0.25 to 100 wt%. As the strength of the interactions is decreased with dilution, the energy barrier is substantially lowered; this will induce a drastic decrease of both the blocking temperatures and the coercivity with decreasing concentration of the nanoparticles
Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence
Chalcones are among the leading bioactive flavonoids with a therapeutic potential implicated to an array of bioactivities investigated by a series of preclinical and clinical studies. In this article, different scientific databases were searched to retrieve studies depicting the biological activities of chalcones and their derivatives. This review comprehensively describes preclinical studies on chalcones and their derivatives describing their immense significance as antidiabetic, anticancer, anti-inflammatory, antimicrobial, antioxidant, antiparasitic, psychoactive, and neuroprotective agents. Besides, clinical trials revealed their use in the treatment of chronic venous insufficiency, skin conditions, and cancer. Bioavailability studies on chalcones and derivatives indicate possible hindrance and improvement in relation to its nutraceutical and pharmaceutical applications. Multifaceted and complex underlying mechanisms of chalcone actions demonstrated their ability to modulate a number of cancer cell lines, to inhibit a number of pathological microorganisms and parasites, and to control a number of signaling molecules and cascades related to disease modification. Clinical studies on chalcones revealed general absence of adverse effects besides reducing the clinical signs and symptoms with decent bioavailability. Further studies are needed to elucidate their structure activity, toxicity concerns, cellular basis of mode of action, and interactions with other molecules
Effect of pressure on nonlinear dynamics and instability of electrically actuated circular micro-plates
Ultrafine NiFe2O4 powder fabricated from reverse microemulsion process
NiFe2O4 ultrafine powder with high crystallinity has been prepared through a reverse microemulsion route. The composition in starting solution was optimized, and the resulting NiFe2O4 was formed at temperature of around 550–600 °C, which is much lower than that observed from the solid-state reaction. Magnetic investigation indicates that samples are soft magnetic materials with low coercivity and with the saturation magnetization close to the bulk value of Ni ferrite. © 2003 American Institute of Physics
Direct electrochemistry of hemoglobin on graphene/Fe3O4 nanocomposite-modified glass carbon electrode and its sensitive detection for hydrogen peroxide
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. METHODS: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. RESULTS: SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced ≥1 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with ≥1 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not ≥5. CONCLUSIONS: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginterferon alfa-2a/ribavirin.This study was sponsored by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Support for third-party writing
assistance for this manuscript, furnished by Blair Jarvis MSc, ELS, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort
Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. Results: SVR24 rates were 46.1 % (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1,2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced 651 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with 651 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not 655. Conclusions: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginter-feron alfa-2a/ribavirin
- …